The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Clinical and pharmacodynamic (PD) results of TEL0805 trial: A phase II study of telatinib (TEL) in combination with capecitabine (X) and cisplatin (P) as first-line treatment in patients (pts) with advanced gastric or gastroesophageal junction (GEJ) cancer.
M. Alsina
Honoraria - ACT Biotech
Other Remuneration - ACT Biotech
A. H. Ko
No relevant relationships to disclose
M. Garcia De Paredes
No relevant relationships to disclose
F. Rivera
No relevant relationships to disclose
L. S. Schwartzberg
No relevant relationships to disclose
A. Fattaey
Employment or Leadership Position - ACT Biotech
Stock Ownership - ACT Biotech
L. A. Kunkel
Employment or Leadership Position - ACT Biotech
Stock Ownership - ACT Biotech
J. Tabernero
No relevant relationships to disclose
J. A. Ajani
Research Funding - ACT Biotech